Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM

This study tests a personalized cell therapy (CAR-T cells engineered to target two proteins — EGFR and IL13Ra2) for people with recurrent glioblastoma (GBM), an aggressive brain cancer that has come back after initial treatment. **You may be eligible if...** - You are 18 or older - You have been diagnosed with glioblastoma (IDH-wildtype, per 2021 WHO criteria) that has recurred after radiation therapy - Your tumor tests positive for EGFR amplification - Surgical resection or biopsy is clinically recommended for your case **You may NOT be eligible if...** - Your tumor does not express the EGFR protein at required levels - You have not yet completed initial radiotherapy - You have certain other health conditions that would make this experimental treatment unsafe Talk to your doctor to see if this trial is right for you.